Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | NAT1 | P18440 | 8/20 | 0.58 |
| ▸ | MYC | P01106 | 2/20 | 0.58 |
| ▸ | MAX | P61244 | 2/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.56 |
| ▸ | CLK1 | P49759 | 2/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.56 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.56 |
| ▸ | CLK3 | P49761 | 1/20 | 0.56 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.56 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16762274 | 1.00 | PIM1 (0.64) | PIM1MEN1RAB9AKMT2ANAT1 | |
| SCHEMBL16762276 | 1.00 | PIM1 (0.64) | PIM1MEN1RAB9AKMT2ANAT1 | |
| SCHEMBL2880695 | 0.88 | RAB9A (0.57) | PIM1RAB9APIK3CAPIK3CGCISD1 | |
| SCHEMBL6794569 | 0.88 | RAB9A (0.57) | PIM1RAB9APIK3CAPIK3CGCISD1 | |
| SCHEMBL2880693 | 0.88 | RAB9A (0.57) | PIM1RAB9APIK3CAPIK3CGCISD1 | |
| SCHEMBL16762261 | 0.84 | MEN1 (0.55) | PIM1MEN1RAB9AKMT2ACLK1 | |
| SCHEMBL16762263 | 0.84 | MEN1 (0.55) | PIM1MEN1RAB9AKMT2ACLK1 | |
| SCHEMBL27985070 | 0.81 | CLK1 (0.46) | PIM1MEN1RAB9AKMT2ACLK1 | |
| SCHEMBL16998368 | 0.79 | CYP2A6 (0.48) | PIM1MEN1RAB9AKMT2ANAT1 | |
| SCHEMBL1250382 | 0.78 | PIM1 (1.00) | PIM1MEN1RAB9AKMT2ANAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114945569-A | Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or Tau-protein related diseases comprising same | 延世大学校产学协力团 | 2022-08-26 | — | — | CN | claimed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| WO-2022255411-A1 | METHOD FOR ENHANCING INNATE IMMUNE RESPONSE | 国立大学法人京都大学 | 2022-12-08 | — | — | WO | disclosed |
| EP-2881397-B1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | UNIV KYOTO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-2881397-B1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | UNIV KYOTO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-9745323-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-9745323-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| CN-106986865-A | On Mental disease or the compound and medical composition of malignant tumour | 国立大学法人京都大学 | 2017-07-28 | — | — | CN | disclosed |
| CN-104520303-B | Compound and pharmaceutical composition for mental and neurological diseases or malignant tumors | 国立大学法人京都大学 | 2017-04-12 | — | — | CN | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| EP-2881397-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | Kyoto University (JP) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881397-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | Kyoto University (JP) | 2015-06-10 | — | — | EP | disclosed |
| CN-104520303-A | Compound and pharmaceutical composition for mental and neurological diseases or malignant tumors | NAT UNIV CORP KYOTO UNIV | 2015-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | VHL, TP53, COMT | PIM1 1202/4885MEN1 31/4885RAB9A 2200/4885 |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | MAPT, APP, PRNP | PIM1 3071/4885MEN1 2152/4885RAB9A 1680/4885 |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | VHL, TP53, COMT | PIM1 1202/4885MEN1 31/4885RAB9A 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.